{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T14:29:58Z","timestamp":1793802598352,"version":"4.6.1"},"reference-count":59,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Pediatr"],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"\n Importance<\/jats:title>\n Obesity affects 1 in 5 children and adolescents, increasing the risk of type 2 diabetes (T2D). Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are among the few pharmacotherapy options available for this population, necessitating a comprehensive evaluation of efficacy and safety.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess the efficacy and safety of GLP-1 RAs in children and adolescents (&amp;lt;18 years) with obesity, prediabetes, or T2D.<\/jats:p>\n <\/jats:sec>\n \n Data Sources<\/jats:title>\n A systematic search was conducted in PubMed, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) for randomized clinical trials (RCTs) published from inception until February 28, 2025. Data analysis was completed from January 2025 to April 2025.<\/jats:p>\n <\/jats:sec>\n \n Study Selection<\/jats:title>\n RCTs comparing GLP-1 RAs to placebo in children and adolescents with obesity, overweight, prediabetes, or T2D with reported safety and efficacy data were included.<\/jats:p>\n <\/jats:sec>\n \n Data Extraction and Synthesis<\/jats:title>\n Two reviewers independently extracted data on sample size, population, interventions, follow-up, and outcomes. Risk of bias was assessed using version 2 of the Cochrane risk of bias tool (RoB2). Efficacy outcomes (except lipids) were analyzed as estimated treatment differences, lipids as estimated treatment ratios, and safety via rate ratios. A random-effects inverse variance model was used for all outcomes.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n \n The primary efficacy outcomes were change in hemoglobin A\n \n 1\n c<\/jats:sc>\n <\/jats:sub>\n (HbA\n \n 1\n c<\/jats:sc>\n <\/jats:sub>\n ) (in percentage points), fasting glucose (in milligrams per deciliter), body weight (in kilograms), body mass index (BMI, calculated as weight in kilograms divided by height in meters squared), BMI\n z<\/jats:italic>\n scores or percentiles, BMI standard deviation score (SDS), lipid outcomes, and blood pressure. Exploratory efficacy outcomes included obstructive sleep apnea and metabolic dysfunction\u2013associated steatohepatitis or metabolic dysfunction\u2013associated steatotic liver disease. Safety outcomes included gastrointestinal adverse effects (GI AEs), infections, hepatobiliary disorders, suicidal ideation or behaviors, depression, hypoglycemia, and adverse event discontinuations.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 18 RCTs (11 in obesity, 6 in T2D, and 1 in prediabetes) with 1402 participants (838 GLP-1 RA users and 564 placebo) were included (mean [range] age, 13.7 [6-17] years; 831 female participants (59.3%); median [IQR] treatment duration, 0.51 [0.25-1.00] years). GLP-1 RAs significantly reduced HbA\n \n 1\n c<\/jats:sc>\n <\/jats:sub>\n (\u22120.44%; 95% CI, \u22120.68% to \u22120.21%), fasting glucose (\u22129.92 mg\/dL; 95% CI, \u221216.20 to \u22123.64), body weight (\u22123.02 kg; 95% CI, \u22124.98 to \u22121.06), BMI (\u22121.45; 95% CI, \u22122.40 to \u22120.49), BMI SDS (\u22120.20; 95% CI, \u22120.36 to \u22120.05), BMI percentile (\u22127.24%; 95% CI, \u221212.97% to \u22121.51%), and systolic blood pressure (\u22122.73 mm Hg; 95% CI, \u22124.04 to \u22121.43) and increased GI AE (log[rate ratio] [RR], 0.75). Other AEs, including suicidal ideation or behaviors, showed no significant differences.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this systematic review and meta-analysis of 18 trials, GLP-1 RAs significantly improved glycemic, weight, and cardiometabolic outcomes in children and adolescents with T2D or obesity. Available data over a relatively short follow-up suggested suicidal ideation or behaviors were not significantly different, although GI AEs warrant attention in long-term management.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamapediatrics.2025.3243","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T15:01:10Z","timestamp":1757948470000},"page":"1308","source":"Crossref","is-referenced-by-count":42,"title":["Efficacy and Safety of GLP-1 RAs in Children and Adolescents With Obesity or Type 2 Diabetes"],"prefix":"10.1001","volume":"179","author":[{"given":"Pareeta","family":"Kotecha","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville"},{"name":"College of Pharmacy, University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxi","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville"},{"name":"College of Pharmacy, University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Yun","family":"Yeh","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville"},{"name":"College of Pharmacy, University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie Martino","family":"Narvaez","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darlene","family":"Adirika","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilin","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelina V.","family":"Bernier","sequence":"additional","affiliation":[{"name":"Division of Pediatric Endocrinology, Department of Pediatrics, College of Medicine, University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah C.","family":"Westen","sequence":"additional","affiliation":[{"name":"Department of Clinical and Health Psychology, College of Public Health and Health Professions, University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville"},{"name":"College of Pharmacy, University of Florida, Gainesville"},{"name":"Center for Drug Evaluation and Safety, University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Bian","sequence":"additional","affiliation":[{"name":"Regenstrief Institute, Indianapolis, Indiana"},{"name":"Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingchuan","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville"},{"name":"College of Pharmacy, University of Florida, Gainesville"},{"name":"Center for Drug Evaluation and Safety, University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"poi250049r2","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2020.581461","article-title":"Childhood and adolescent obesity: a review.","volume":"8","author":"Kansra","year":"2021","journal-title":"Front Pediatr"},{"key":"poi250049r3","doi-asserted-by":"publisher","DOI":"10.1177\/2333794X19891305","article-title":"Childhood and adolescent obesity in the United States: a public health concern.","author":"Sanyaolu","year":"2019","journal-title":"Glob Pediatr Health"},{"issue":"7","key":"poi250049r5","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.63952","article-title":"The role of screening, risk factors, and early intervention in preventing diabetes in the obese population: a systematic review.","volume":"16","author":"Merwass","year":"2024","journal-title":"Cureus"},{"issue":"12","key":"poi250049r6","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.3390\/children9121975","article-title":"Risk factors, clinical consequences, prevention, and treatment of childhood obesity.","volume":"9","author":"Shaban Mohamed","year":"2022","journal-title":"Children (Basel)"},{"issue":"1","key":"poi250049r7","first-page":"1","article-title":"Childhood obesity: a global public health crisis.","volume":"3","author":"Karnik","year":"2012","journal-title":"Int J Prev Med"},{"issue":"2","key":"poi250049r8","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2022-060640","article-title":"Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity.","volume":"151","author":"Hampl","year":"2023","journal-title":"Pediatrics"},{"key":"poi250049r9","doi-asserted-by":"publisher","first-page":"S258","DOI":"10.2337\/dc24-S014","article-title":"14. Children and adolescents: standards of care in diabetes-2024.","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","journal-title":"Diabetes Care"},{"issue":"6","key":"poi250049r10","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1159\/000543033","article-title":"ISPAD Clinical Practice Consensus Guidelines 2024: type 2 diabetes in children and adolescents.","volume":"97","author":"Shah","year":"2024","journal-title":"Horm Res Paediatr"},{"issue":"23","key":"poi250049r11","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1001\/jama.2024.7112","article-title":"Dispensing of glucagon-like peptide-1 receptor agonists to adolescents and young adults, 2020-2023.","volume":"331","author":"Lee","year":"2024","journal-title":"JAMA"},{"issue":"1","key":"poi250049r15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jagp.2023.08.010","article-title":"The antidepressant effects of GLP-1 receptor agonists: a systematic review and meta-analysis.","volume":"32","author":"Chen","year":"2024","journal-title":"Am J Geriatr Psychiatry"},{"issue":"4","key":"poi250049r16","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1007\/s43440-021-00274-8","article-title":"Insights into a possible role of glucagon-like peptide-1 receptor agonists in the treatment of depression.","volume":"73","author":"Detka","year":"2021","journal-title":"Pharmacol Rep"},{"issue":"2","key":"poi250049r17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.su7102a1","article-title":"Mental health surveillance among children - United States, 2013-2019.","volume":"71","author":"Bitsko","year":"2022","journal-title":"MMWR Suppl"},{"key":"poi250049r18","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.psyneuen.2015.11.021","article-title":"GLP-1 is both anxiogenic and antidepressant; divergent effects of acute and chronic GLP-1 on emotionality.","volume":"65","author":"Anderberg","year":"2016","journal-title":"Psychoneuroendocrinology"},{"issue":"1","key":"poi250049r19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/14656566.2024.2437525","article-title":"Current perspectives on the use of GLP-1 receptor agonists in obesity-related obstructive sleep apnea: a narrative review.","volume":"26","author":"El-Solh","year":"2025","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"poi250049r21","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13177","article-title":"GLP-1 agonists for obesity and type 2 diabetes in children: systematic review and meta-analysis.","volume":"22","author":"Chadda","year":"2021","journal-title":"Obes Rev"},{"issue":"1","key":"poi250049r22","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13098-024-01337-5","article-title":"The efficacy and safety of GLP-1 receptor agonists in youth with type 2 diabetes: a meta-analysis.","volume":"16","author":"Yugar","year":"2024","journal-title":"Diabetol Metab Syndr"},{"key":"poi250049r23","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jpeds.2021.05.009","article-title":"Safety and efficacy of glucagon-like peptide-1 receptor agonists in children and adolescents with obesity: a meta-analysis.","volume":"236","author":"Ryan","year":"2021","journal-title":"J Pediatr"},{"issue":"4","key":"poi250049r24","doi-asserted-by":"crossref","first-page":"580","DOI":"10.5195\/jmla.2018.513","article-title":"Covidence and Rayyan.","volume":"106","author":"Kellermeyer","year":"2018","journal-title":"J Med Libr Assoc"},{"issue":"4","key":"poi250049r25","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1097\/01.XEB.0000511346.12446.f2","article-title":"Covidence vs Excel for the title and abstract review stage of a systematic review.","volume":"14","author":"Macdonald","year":"2016","journal-title":"Int J Evid-Based Healthc"},{"key":"poi250049r31","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"7","key":"poi250049r32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"2","key":"poi250049r34","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/oby.2011.337","article-title":"Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study.","volume":"20","author":"Kelly","year":"2012","journal-title":"Obesity (Silver Spring)"},{"issue":"4","key":"poi250049r35","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1001\/jamapediatrics.2013.1045","article-title":"The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial.","volume":"167","author":"Kelly","year":"2013","journal-title":"JAMA Pediatr"},{"issue":"22","key":"poi250049r36","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","article-title":"A randomized, controlled trial of liraglutide for adolescents with obesity.","volume":"382","author":"Kelly","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"poi250049r37","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1210\/clinem\/dgac549","article-title":"Liraglutide for weight management in children and adolescents with Prader-Willi syndrome and obesity.","volume":"108","author":"Diene","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"poi250049r38","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1056\/NEJMoa1903822","article-title":"Liraglutide in children and adolescents with type 2 diabetes.","volume":"381","author":"Tamborlane","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"poi250049r39","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2213-8587(22)00052-3","article-title":"Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study.","volume":"10","author":"Tamborlane","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"poi250049r40","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jpeds.2016.10.076","article-title":"Liraglutide in an adolescent population with obesity: a randomized, double-blind, placebo-controlled 5-week trial to assess safety, tolerability, and pharmacokinetics of liraglutide in adolescents aged 12-17 years.","volume":"181","author":"Danne","year":"2017","journal-title":"J Pediatr"},{"issue":"6","key":"poi250049r41","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1056\/NEJMoa2407379","article-title":"Liraglutide for children 6 to <12 years of age with obesity - a randomized trial.","volume":"392","author":"Fox","year":"2025","journal-title":"N Engl J Med"},{"issue":"7","key":"poi250049r42","doi-asserted-by":"publisher","DOI":"10.1111\/ijpo.12624","article-title":"A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity.","volume":"15","author":"Weghuber","year":"2020","journal-title":"Pediatr Obes"},{"issue":"24","key":"poi250049r43","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","article-title":"Once-weekly semaglutide in adolescents with obesity.","volume":"387","author":"Weghuber","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"poi250049r44","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1089\/dia.2013.0366","article-title":"Liraglutide\u2019s safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial.","volume":"16","author":"Klein","year":"2014","journal-title":"Diabetes Technol Ther"},{"issue":"5","key":"poi250049r45","doi-asserted-by":"publisher","DOI":"10.1111\/ijpo.12495","article-title":"Liraglutide effects in a paediatric (7-11 y) population with obesity: a randomized, double-blind, placebo-controlled, short-term trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics.","volume":"14","author":"Mastrandrea","year":"2019","journal-title":"Pediatr Obes"},{"issue":"5","key":"poi250049r46","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1056\/NEJMoa2204601","article-title":"Once-weekly dulaglutide for the treatment of youths with type 2 diabetes.","volume":"387","author":"Arslanian","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"poi250049r47","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/pedi.13343","article-title":"A study on pharmacokinetics, pharmacodynamics and safety of lixisenatide in children and adolescents with type 2 diabetes.","volume":"23","author":"Barrientos-P\u00e9rez","year":"2022","journal-title":"Pediatr Diabetes"},{"issue":"2","key":"poi250049r48","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/dom.14224","article-title":"A phase 3 randomized clinical trial using a once-weekly glucagon-like peptide-1 receptor agonist in adolescents and young adults with hypothalamic obesity.","volume":"23","author":"Roth","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"poi250049r49","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.3892\/etm.2017.4129","article-title":"The effects of GLP-1 analogues on pre-diabetes of the children.","volume":"13","author":"Zhou","year":"2017","journal-title":"Exp Ther Med"},{"issue":"5","key":"poi250049r51","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1002\/oby.23395","article-title":"Exenatide for weight-loss maintenance in adolescents with severe obesity: a randomized, placebo-controlled trial.","volume":"30","author":"Fox","year":"2022","journal-title":"Obesity (Silver Spring)"},{"issue":"6","key":"poi250049r52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126769","article-title":"The effect of glucagon-like peptide 1 receptor agonists on weight loss in type 2 diabetes: a systematic review and mixed treatment comparison meta-analysis.","volume":"10","author":"Potts","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"poi250049r53","doi-asserted-by":"publisher","first-page":"292","DOI":"10.2337\/dc24-1678","article-title":"Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: a systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials.","volume":"48","author":"Wong","year":"2025","journal-title":"Diabetes Care"},{"key":"poi250049r54","doi-asserted-by":"crossref","DOI":"10.1161\/circ.150.suppl_1.4129733","article-title":"Abstract 4129733: glucagon-like peptide 1 receptor agonists effect on low-density lipoprotein cholesterol and total cholesterol levels independent of weight reduction: a meta-analysis and meta-regression of placebo-controlled randomized controlled trials.","volume":"150","author":"Rivera","year":"2024","journal-title":"Circulation"},{"issue":"1","key":"poi250049r55","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.diabres.2015.07.015","article-title":"Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis.","volume":"110","author":"Sun","year":"2015","journal-title":"Diabetes Res Clin Pract"},{"key":"poi250049r56","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.sleep.2025.02.010","article-title":"Efficacy and safety of GLP-1 receptor agonists in the management of obstructive sleep apnea in individuals without diabetes: a systematic review and meta-analysis of randomized, placebo-controlled trials.","volume":"129","author":"Kow","year":"2025","journal-title":"Sleep Med"},{"issue":"8","key":"poi250049r57","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.7326\/M24-0329","article-title":"Glucagon-like peptide-1 receptor agonists and risk for suicidal ideation and behaviors in U.S. older adults with type 2 diabetes: a target trial emulation study.","volume":"177","author":"Tang","year":"2024","journal-title":"Ann Intern Med"},{"issue":"3","key":"poi250049r58","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1111\/dom.16147","article-title":"Assessing the benefit-risk profile of newer glucose-lowering drugs: a systematic review and network meta-analysis of randomized outcome trials.","volume":"27","author":"Tang","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"poi250049r59","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1016\/j.jval.2024.03.266","article-title":"CO180 newer glucose-lowering drugs and risk of depression: a meta-analysis of randomized outcome trials.","volume":"27","author":"Tang","year":"2024","journal-title":"Value Health"},{"key":"poi250049r28","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.5","author":"Higgins","year":"2024"},{"key":"poi250049r30","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.5","author":"Deeks","year":"2024"},{"key":"poi250049r1","unstructured":"US Centers for Disease Control and Prevention. Childhood obesity facts. Accessed September 19, 2024. https:\/\/www.cdc.gov\/obesity\/childhood-obesity-facts\/childhood-obesity-facts.html"},{"key":"poi250049r4","unstructured":"US Centers for Disease Prevention and Control. Diabetes. Accessed April 30, 2025. https:\/\/www.cdc.gov\/diabetes\/index.html"},{"key":"poi250049r12","unstructured":"European Medicines Agency. EMA statement on ongoing review of GLP-1 receptor agonists. Accessed April 12, 2025. https:\/\/www.ema.europa.eu\/en\/news\/ema-statement-ongoing-review-glp-1-receptor-agonists"},{"key":"poi250049r13","unstructured":"US Food and Drug Administration. Update on FDA\u2019s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity. Accessed April 12, 2025. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type"},{"key":"poi250049r14","unstructured":"American Academy of Pediatrics. Suicide: pediatric mental health minute series. https:\/\/www.aap.org\/en\/patient-care\/mental-health-minute\/suicide\/?srsltid=AfmBOopLIXdOWEe-DbiXwROQ0mRVP4vyNrSiqsCDaVfac5ycBTWG43IG"},{"key":"poi250049r20","unstructured":"US Food and Drug Administarion. FDA approves first medication for obstructive sleep apnea. Accessed April 1, 2025. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-medication-obstructive-sleep-apnea"},{"key":"poi250049r26","unstructured":"Center for Drug Evaluation and Research. Guidance for industry: suicidal ideation and behavior: prospective assessment of occurrence in clinical trials. Accessed March 31, 2025. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-suicidal-ideation-and-behavior-prospective-assessment-occurrence-clinical-trials"},{"key":"poi250049r27","unstructured":"Society for Biomedical Diabetes Research. Conversion of glucose values from mg\/dl to mmol\/l. Accessed March 22, 2025. http:\/\/www.soc-bdr.org\/rds\/authors\/unit_tables_conversions_and_genetic_dictionaries\/conversion_glucose_mg_dl_to_mmol_l\/index_en.html"},{"key":"poi250049r29","unstructured":"Deeks? JJ, Higgins? JPT; Statistical Methods Group of The Cochrane Collaboration. Statistical algorithms in Review Manager. Accessed March 22, 2025. https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/statistical-methods-revman5"},{"key":"poi250049r33","unstructured":"Kotecha? P, Huang? W, Yeh? YY, Narvaez? VM, Guo? J. The use of glucagon like peptide-1 receptor agonists in children & adolescents with type 2 diabetes and\/or obesity. UK National Institute for Health and Care Research. Accessed March 22, 2025. https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD42024583356"},{"key":"poi250049r50","unstructured":"AstraZeneca. Safety and efficacy of exenatide as monotherapy and adjunctive therapy to oral antidiabetic agents in adolescents with type 2 diabetes. Accessed March 22, 2025. https:\/\/www.astrazenecaclinicaltrials.com\/study\/D5550C00002\/"}],"container-title":["JAMA Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapediatrics\/articlepdf\/2838307\/jamapediatrics_kotecha_2025_oi_250049_1763487244.26147.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T16:01:05Z","timestamp":1764604865000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapediatrics\/fullarticle\/2838307"}},"subtitle":["A Systematic Review and Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":59,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapediatrics.2025.3243","relation":{},"ISSN":["2168-6203"],"issn-type":[{"value":"2168-6203","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,1]]}}}